Pharma BD Heads Weigh The Benefits Of Corporate Venture Investing
This article was originally published in The Pink Sheet Daily
Executive Summary
Heads of business development from some of the world's largest pharmaceutical companies weigh in on the role business development plays in accessing tomorrow's innovations at the recent PSA conference.
You may also be interested in...
Biogen Ends Its Corporate Venture Efforts
Biogen CEO George Scangos spoke about the unnecessary overlap of the company's corporate venture fund and its business development unit at Windhover's recent Pharmaceutical Strategic Alliance conference.
Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
IN an effort to forge earlier and stronger ties to venture-backed biotechs, the new Merck Research Venture Fund illustrates the lure -- and the limitations -- of strategic pharma-VC relationships. Merck has endowed the MRVF with $250 million and the fund will make a series of investments in life science venture capital firms around the globe. Simultaneously it has also staked a second fund, the Global Health Innovation Fund, with an additional $250 million to invest in later-stage companies outside of the drug area.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.